science

Sclerosing epithelioid fibrosarcoma

Sclerosing epithelioid fibrosarcoma is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Sclerosing epithelioid fibrosarcoma rather than just read about it. In short: Sclerosing epithelioid fibrosarcoma (SEF) is a very rare malignant tumor of soft tissues that on microscopic examination consists of small round or ovoid neoplastic epithelioid fibroblast-like cells, i.e. cells that have features resembling both epithelioid cells and fibroblasts. In 2020, the World Health Organization classified SEF as a distinct tumor type in the category of malignant fibroblastic and myofibroblast…

Key takeaways

Sclerosing epithelioid fibrosarcoma belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Sclerosing epithelioid fibrosarcoma to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Sclerosing epithelioid fibrosarcoma from memory before moving on to harder problems.

Reference excerpt

Sclerosing epithelioid fibrosarcoma (SEF) is a very rare malignant tumor of soft tissues that on microscopic examination consists of small round or ovoid neoplastic epithelioid fibroblast-like cells, i.e. cells that have features resembling both epithelioid cells and fibroblasts. In 2020, the World Health Organization classified SEF as a distinct tumor type in the category of malignant fibroblastic and myofibroblastic tumors. However, current studies have reported that low-grade fibromyxoid sarcoma (LGFMS) has many clinically and pathologically important features characteristic of SEF; these studies suggest that LGSFMS may be an early form of, and over time progress to become, a SEF. Since the World Health Organization has classified LGFMS as one of the malignant fibroblastic and myofibroblastic tumors that is distinctly different than SEF, SEF and LGFMS are here regarded as different tumor forms. Sclerosing epithelioid fibrosarcomas are aggressive tumors that usually develop in adults and elderly individuals or, in a small minority of cases, children. SEF tumors often occur in a shoulder, hip, or lower areas of the legs and arms or, less commonly, in a vital organ or other tissue location that may be in virtually any part of the body. SEF tumors tend to recur at the site where they are surgically removed, to metastasize to other tissues, and to have poor outcomes. Surgical resection of the primary or recurrent tumor with or without adjuvant radiation therapy has been the mainstay treatment for SEF. This treatment is often employed in order to achieve control of the tumor's local injurious effects. The sensitivity of SEF tumors to various chemotherapy regimens has been very limited. The prognosis of SEF is guarded because surgery with or without radiation therapy and chemotherapy frequently does not stop, or only stops for a short time, the progression of this disease.

Presentation Individuals presenting with SEF tumors are 3 to 87 years old (median age 44.6 years) with most individuals aged 30-60 years. These tumors involve the lower limb and shoulder areas (28.3% of cases), trunk (18.7%), head and neck areas (11.7%), lung and its pleura (10.0%), bone (including the spinal vertebrae) (10.0%), soft tissues (9.1%), upper limb and shoulder areas (7.5%), kidney (3.9%), pancreas (0.9%), liver (0.4%), and brain (0.4%). Rare cases of SEF tumors have developed in the ovary and lower gastrointestinal tract. In two separate studies, 17% and 27% of patients presented with metastases at the time of the initial diagnosis of their disease. While most individuals present with a painless mass, about 33% report having a painful and enlarging mass. The tumor may have been noticed and even painful for a few months to years. Tumors developing in the head, abdominal cavity, or other space-constrained sites often present with symptoms and signs related to their tumors' mass effects. For example, 5 of 5 patients diagnosed with SEF tumors in the spinal vertebrae presented with pain that they had experienced for 3 to 6 months and 2 of 2 patients with a SEF located in the buttock presented with highly painful sciatica. SEF tumors have varied in size from 1 to 25 cm in diameter (average diameter, 8.3 cm). In one small study, all individuals treated with surgical resection of their tumors, re-presented with recurrences of their tumors at the sites of their surgical removal and 91% re-presented with metastases (67% to the lung, 50% to bone, and 1 case each to the liver, brain and abdomen).

Pathology As defined by microscopic histopathologic analyses of hematoxylin and eosin stained tissue samples, SEF tumors vary from lower to higher cellular lesions. These cells are small-to-moderate-sized epitheliod-like cells that on ultrastructural analyses have features of fibroblasts and myofibroblasts. The cells contain moderate numbers of mitochondria, abundant rough endoplasmic reticulum networks, large Golgi complexes, and cytoplasmic arrays of vimentin intermediate filaments. The cells tend to be grouped into nests, sheets, cords, and/or single files embedded in an eosinophilic (i.e. more blue or purple compared to normal connective tissue because of excessive uptake of the hematoxylin stain), sclerotic (i.e. hardened) connective tissue background. The connective tissue background contains irregular, thin-walled, distended blood vessels and may have foci of hyaline cartilage, bone formation, and necrosis (clumps of dead or dying cells). Immunohistochemical analyses find that the neoplastic cells in SEF tumors typically express MUC1, vimentin, Bcl-2, CD99, and MUC4 marker proteins. MUC1, vimentin, CD99, and Bcl-2 marker proteins are expressed in the neoplastic cells of various types of other tumors and therefore do not distinguish between these tumors and SEF. However the expression of MUC4 is found mainly in the neoplastic cells of SEF and low-grade fibroblastic tumors. Consequently, the expression of the MUC4 marker protein in tumor cells suggests that these tumors are either a SEF or low-grade fibromyxoid sarcoma rather than certain mimickers of SEF. SEF tumors with MUC4-negative neoplastic cells may be more aggressive than SEF tumors with MUC4-positive neoplastic cells.

… excerpt ends here. Continue reading the full article.

Worked examples

Example 1 — a first encounter with Sclerosing epithelioid fibrosarcoma

Start with the simplest possible case. Write down what Sclerosing epithelioid fibrosarcoma claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Sclerosing epithelioid fibrosarcoma before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Sclerosing epithelioid fibrosarcoma ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Sclerosing epithelioid fibrosarcoma

In research: Sclerosing epithelioid fibrosarcoma appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Sclerosing epithelioid fibrosarcoma in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Sclerosing epithelioid fibrosarcoma is common in secondary-school and first-year university syllabi. It links to neighbouring topics Connective and soft tissue neoplasms, Dermal and subcutaneous growths, Medical condition modules, so understanding it makes those chapters shorter.
In everyday life: Look for Sclerosing epithelioid fibrosarcoma outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Sclerosing epithelioid fibrosarcoma” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Sclerosing epithelioid fibrosarcoma in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Sclerosing epithelioid fibrosarcoma means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Sclerosing epithelioid fibrosarcoma out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Sclerosing epithelioid fibrosarcoma in simple terms?

Why does Sclerosing epithelioid fibrosarcoma matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Sclerosing epithelioid fibrosarcoma?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Sclerosing epithelioid fibrosarcoma.